The administrative core of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center will coordinate the activities within and outside the Center as well as promote an interactive and collaborative research environment. The responsibilities of Core A include the following: organization of the flow of project information, distribution of research effort, allocation of budgetary and other resources, preparing annual budgets and projections, scheduling and facilitating regular Muscle Disease Neuropathology Conference meetings, and consulting the Dean regarding progress, scientific direction, administrative issues and concerns, and future plans. The scientific responsibilities of Core A include the following: scientific integration, coordination, and direction of research projects as needed, consultation with advisors and consultants concerning importance and progress of the research as it relates to other current and developing muscular dystrophy research, identifying seminar speakers and coordinating their participation and contributions to the Center, and holding an annual retreat for the Center Investigators. This core will also facilitate expansion of our collaboration with national and international leaders in the field of congenital/limbgirdle muscular dystrophy. The Core A Administrator coordinates an annual open house for the Muscular Dystrophy Association located in Cedar Rapids, lowa which hosts seminars for approximately 100 patients/families to discuss current and upcoming research and advancements in muscular dystrophy. The Administrator is also responsible for coordinating the Wellstone Steering Committee Face to Face Meeting when hosted by the University of lowa, coordinating meetings among Core Directors and Project Leaders, and coordinating patient/family tours.

Public Health Relevance

The administrative core of our MDCRC renewal will coordinate the overall mission of the MDCRC by providing essential administrative support (for example tracking the budget and coordinating patient visits) for the two two projects and other cores in order to accelerate the tempo of discovery in preclinical translational research and the achievement of clinical trial readiness.

National Institute of Health (NIH)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Iowa City
United States
Zip Code
Bönnemann, Carsten G; Wang, Ching H; Quijano-Roy, Susana et al. (2014) Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord 24:289-311
Inamori, Kei-ichiro; Willer, Tobias; Hara, Yuji et al. (2014) Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of ?-dystroglycan in cells and tissues. J Biol Chem 289:28138-48
Chauveau, Claire; Bonnemann, Carsten G; Julien, Cedric et al. (2014) Recessive TTN truncating mutations define novel forms of core myopathy with heart disease. Hum Mol Genet 23:980-91
Wallace, Stephanie E; Conta, Jessie H; Winder, Thomas L et al. (2014) A novel missense mutation in POMT1 modulates the severe congenital muscular dystrophy phenotype associated with POMT1 nonsense mutations. Neuromuscul Disord 24:312-20
Willer, Tobias; Inamori, Kei-Ichiro; Venzke, David et al. (2014) The glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated ?-dystroglycan functional glycosylation. Elife 3:
Crockett, Cameron D; Ruggieri, Alessandra; Gujrati, Meena et al. (2014) Late adult-onset of X-linked myopathy with excessive autophagy. Muscle Nerve 50:138-44
Goddeeris, Matthew M; Wu, Biming; Venzke, David et al. (2013) LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy. Nature 503:136-40
Cirak, Sebahattin; Foley, Aileen Reghan; Herrmann, Ralf et al. (2013) ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain 136:269-81
Yang, Amy C; Ng, Bobby G; Moore, Steven A et al. (2013) Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy. Mol Genet Metab 110:345-51
Stevens, Elizabeth; Carss, Keren J; Cirak, Sebahattin et al. (2013) Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of *-dystroglycan. Am J Hum Genet 92:354-65

Showing the most recent 10 out of 47 publications